Evaluation of Chelator-to-Antibody Ratio on Development of ⁸⁹Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor.

ABSTRACT: ⁸⁹Zr-iPET has been widely used for preclinical and clinical immunotherapy studies to predict patient stratification or evaluate therapeutic efficacy. In this study, we prepared and evaluated ⁸⁹Zr-DFO-anti-PD-L1-mAb tracers with varying chelator-to-antibody ratios (CARs), including ⁸⁹Zr-DFO-anti-PD-L1-mAb_3X (tracer_3X), ⁸⁹Zr-DFO-anti-PD-L1-mAb_10X (tracer_10X), and ⁸⁹Zr-DFO-anti-PD-L1-mAb_20X (tracer_20X). The DFO-anti-PD-L1-mAb conjugates with varying CARs were prepared using a random conjugation method and then subjected to quality control. The conjugates were radiolabeled with ⁸⁹Zr and evaluated in a PD-L1-expressing CT26 tumor-bearing mouse model. Next, iPET imaging, biodistribution, pharmacokinetics

SUBMITTER: Tsai SC 

PROVIDER: S-EPMC10743313 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature